|
1
|
Jeong H, Kim J, Lee Y, Seo JH, Hong SR and
Kim A: Neuregulin-1 induces cancer stem cell characteristics in
breast cancer cell lines. Oncol Rep. 32:1218–1224. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gupta PB, Chaffer CL and Weinberg RA:
Cancer stem cells: Mirage or reality? Nat Med. 15:1010–1012. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Visvader JE and Lindeman GJ: Cancer stem
cells: Current status and evolving complexities. Cell Stem Cell.
10:717–728. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen W, Fan XM, Mao L, Zhang JY, Li J, Wu
JZ and Tang JH: MicroRNA-224: As a potential target for miR-based
therapy of cancer. Tumour Biol. 36:6645–6652. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang D, Zhou P, Wang W, Wang X, Li J, Sun
X and Zhang L: MicroRNA-616 promotes the migration, invasion and
epithelial-mesenchymal transition of HCC by targeting PTEN. Oncol
Rep. 35:366–374. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
El Helou R, Pinna G, Cabaud O, Wicinski J,
Bhajun R, Guyon L, Rioualen C, Finetti P, Gros A, Mari B, et al:
miR-600 acts as a bimodal switch that regulates breast cancer stem
cell fate through WNT signaling. Cell Rep. 18:2256–2268. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu Y, Zhang J, Sun X, Su Q and You C:
Down-regulation of miR-29b in carcinoma associated fibroblasts
promotes cell growth and metastasis of breast cancer. Oncotarget.
8:39559–39570. 2017.PubMed/NCBI
|
|
8
|
Calin GA, Ferracin M, Cimmino A, Di Leva
G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et
al: A MicroRNA signature associated with prognosis and progression
in chronic lymphocytic leukemia. N Engl J Med. 353:1793–1801. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fang Y, Xiang J, Chen Z, Gu X, Li Z, Tang
F and Zhou Z: miRNA expression profile of colon cancer stem cells
compared to non-stem cells using the SW1116 cell line. Oncol Rep.
28:2115–2124. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dontu G, Abdallah WM, Foley JM, Jackson
KW, Clarke MF, Kawamura MJ and Wicha MS: In vitro propagation and
transcriptional profiling of human mammary stem/progenitor cells.
Genes Dev. 17:1253–1270. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chang CJ, Chao CH, Xia W, Yang JY, Xiong
Y, Li CW, Yu WH, Rehman SK, Hsu JL, Lee HH, et al: p53 regulates
epithelial-mesenchymal transition and stem cell properties through
modulating miRNAs. Nat Cell Biol. 13:317–323. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
van den Beucken T, Koch E, Chu K,
Rupaimoole R, Prickaerts P, Adriaens M, Voncken JW, Harris AL,
Buffa FM, Haider S, et al: Hypoxia promotes stem cell phenotypes
and poor prognosis through epigenetic regulation of DICER. Nat
Commun. 5:52032014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smith AL, Iwanaga R, Drasin DJ, Micalizzi
DS, Vartuli RL, Tan AC and Ford HL: The miR-106b-25 cluster targets
Smad7, activates TGF-β signaling, and induces EMT and tumor
initiating cell characteristics downstream of Six1 in human breast
cancer. Oncogene. 31:5162–5171. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Q, Yao Y, Eades G, Liu Z, Zhang Y and
Zhou Q: Downregulation of miR-140 promotes cancer stem cell
formation in basal-like early stage breast cancer. Oncogene.
33:2589–2600. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kang L, Mao J, Tao Y, Song B, Ma W, Lu Y,
Zhao L, Li J, Yang B and Li L: MicroRNA-34a suppresses the breast
cancer stem cell-like characteristics by downregulating Notch1
pathway. Cancer Sci. 106:700–708. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chao CH, Chang CC, Wu MJ, Ko HW, Wang D,
Hung MC, Yang JY and Chang CJ: MicroRNA-205 signaling regulates
mammary stem cell fate and tumorigenesis. J Clin Invest.
124:3093–3106. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang H, Cai K, Wang J, Wang X, Cheng K,
Shi F, Jiang L, Zhang Y and Dou J: MiR-7, inhibited indirectly by
lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of
breast cancer stem cells by downregulating the STAT3 pathway. Stem
Cells. 32:2858–2868. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang X, Lu H, Li T, Yu L, Liu G, Peng X
and Zhao J: Krüppel-like factor 8 promotes tumorigenic mammary stem
cell induction by targeting miR-146a. Am J Cancer Res. 3:356–373.
2013.PubMed/NCBI
|
|
20
|
Han M, Liu M, Wang Y, Chen X, Xu J, Sun Y,
Zhao L, Qu H, Fan Y and Wu C: Antagonism of miR-21 reverses
epithelial-mesenchymal transition and cancer stem cell phenotype
through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One.
7:e395202012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nandy SB, Arumugam A, Subramani R, Pedroza
D, Hernandez K, Saltzstein E and Lakshmanaswamy R: MicroRNA-125a
influences breast cancer stem cells by targeting leukemia
inhibitory factor receptor which regulates the Hippo signaling
pathway. Oncotarget. 6:17366–17378. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu F, Jiao Y, Zhu Y, Wang Y, Zhu J, Cui X,
Liu Y, He Y, Park EY, Zhang H, et al: MicroRNA 34c gene
down-regulation via DNA methylation promotes self-renewal and
epithelial-mesenchymal transition in breast tumor-initiating cells.
J Biol Chem. 287:465–473. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Finlay-Schultz J, Cittelly DM, Hendricks
P, Patel P, Kabos P, Jacobsen BM, Richer JK and Sartorius CA:
Progesterone downregulation of miR-141 contributes to expansion of
stem-like breast cancer cells through maintenance of progesterone
receptor and Stat5a. Oncogene. 34:3676–3687. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Polytarchou C, Iliopoulos D and Struhl K:
An integrated transcriptional regulatory circuit that reinforces
the breast cancer stem cell state. Proc Natl Acad Sci USA.
109:14470–14475. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Iliopoulos D, Lindahl-Allen M, Polytarchou
C, Hirsch HA, Tsichlis PN and Struhl K: Loss of miR-200 inhibition
of Suz12 leads to polycomb-mediated repression required for the
formation and maintenance of cancer stem cells. Mol Cell.
39:761–772. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wellner U, Schubert J, Burk UC,
Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D,
zur Hausen A, et al: The EMT-activator ZEB1 promotes tumorigenicity
by repressing stemness-inhibiting microRNAs. Nat Cell Biol.
11:1487–1495. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Knezevic J, Pfefferle AD, Petrovic I,
Greene SB, Perou CM and Rosen JM: Expression of miR-200c in
claudin-low breast cancer alters stem cell functionality, enhances
chemosensitivity and reduces metastatic potential. Oncogene.
34:5997–6006. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Iliopoulos D, Polytarchou C,
Hatziapostolou M, Kottakis F, Maroulakou IG, Struhl K and Tsichlis
PN: MicroRNAs differentially regulated by Akt isoforms control EMT
and stem cell renewal in cancer cells. Sci Signal. 2:ra622009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang X, Wan G, Mlotshwa S, Vance V,
Berger FG, Chen H and Lu X: Oncogenic Wip1 phosphatase is inhibited
by miR-16 in the DNA damage signaling pathway. Cancer Res.
70:7176–7186. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kastrati I, Canestrari E and Frasor J:
PHLDA1 expression is controlled by an estrogen
receptor-NFκB-miR-181 regulatory loop and is essential for
formation of ER+ mammospheres. Oncogene. 34:2309–2316. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vazquez-Martin A, Cufí S, López-Bonet E,
Corominas-Faja B, Cuyàs E, Vellon L, Iglesias JM, Leis O, Martín AG
and Menendez JA: Reprogramming of non-genomic estrogen signaling by
the stemness factor SOX2 enhances the tumor-initiating capacity of
breast cancer cells. Cell Cycle. 12:3471–3477. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Y, Eades G, Yao Y, Li Q and Zhou Q:
Estrogen receptor α signaling regulates breast tumor-initiating
cells by down-regulating miR-140 which targets the transcription
factor SOX2. J Biol Chem. 287:41514–41522. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu S, Patel SH, Ginestier C, Ibarra I,
Martin-Trevino R, Bai S, McDermott SP, Shang L, Ke J, Ou SJ, et al:
MicroRNA93 regulates proliferation and differentiation of normal
and malignant breast stem cells. PLoS Genet. 8:e10027512012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liao J, Liu PP, Hou G, Shao J, Yang J, Liu
K, Lu W, Wen S, Hu Y and Huang P: Regulation of stem-like cancer
cells by glutamine through β-catenin pathway mediated by redox
signaling. Mol Cancer. 16:512017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang Z, Han Y, Cheng K, Zhang G and Wang
X: miR-99a directly targets the mTOR signalling pathway in breast
cancer side population cells. Cell Prolif. 47:587–595. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Majumder M, Landman E, Liu L, Hess D and
Lala PK: COX-2 elevates oncogenic miR-526b in breast cancer by EP4
activation. Mol Cancer Res. 13:1022–1033. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cittelly DM, Finlay-Schultz J, Howe EN,
Spoelstra NS, Axlund SD, Hendricks P, Jacobsen BM, Sartorius CA and
Richer JK: Progestin suppression of miR-29 potentiates
dedifferentiation of breast cancer cells via KLF4. Oncogene.
32:2555–2564. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shimono Y, Zabala M, Cho RW, Lobo N,
Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, et al:
Downregulation of miRNA-200c links breast cancer stem cells with
normal stem cells. Cell. 138:592–603. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Petrelli A, Carollo R, Cargnelutti M,
Iovino F, Callari M, Cimino D, Todaro M, Mangiapane LR, Giammona A,
Cordova A, et al: By promoting cell differentiation, miR-100
sensitizes basal-like breast cancer stem cells to hormonal therapy.
Oncotarget. 6:2315–2330. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chiotaki R, Polioudaki H and
Theodoropoulos PA: Cancer stem cells in solid and liquid tissues of
breast cancer patients: Characterization and therapeutic
perspectives. Curr Cancer Drug Targets. 15:256–269. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Han M, Wang Y, Liu M, Bi X, Bao J, Zeng N,
Zhu Z, Mo Z, Wu C and Chen X: MiR-21 regulates
epithelial-mesenchymal transition phenotype and hypoxia-inducible
factor-1α expression in third-sphere forming breast cancer stem
cell-like cells. Cancer Sci. 103:1058–1064. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Han M, Liu M, Wang Y, Mo Z, Bi X, Liu Z,
Fan Y, Chen X and Wu C: Re-expression of miR-21 contributes to
migration and invasion by inducing epithelial-mesenchymal
transition consistent with cancer stem cell characteristics in
MCF-7 cells. Mol Cell Biochem. 363:427–436. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Song SJ, Poliseno L, Song MS, Ala U,
Webster K, Ng C, Beringer G, Brikbak NJ, Yuan X, Cantley LC, et al:
MicroRNA-antagonism regulates breast cancer stemness and metastasis
via TET-family-dependent chromatin remodeling. Cell. 154:311–324.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lin Y, Liu AY, Fan C, Zheng H, Li Y, Zhang
C, Wu S, Yu D, Huang Z, Liu F, et al: MicroRNA-33b inhibits breast
cancer metastasis by targeting HMGA2, SALL4 and Twist1. Sci Rep.
5:99952015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Huang S, Cai M, Zheng Y, Zhou L, Wang Q
and Chen L: miR-888 in MCF-7 side population sphere cells directly
targets E-cadherin. J Genet Genomics. 41:35–42. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hwang-Verslues WW, Chang PH, Wei PC, Yang
CY, Huang CK, Kuo WH, Shew JY, Chang KJ, Lee EY and Lee WH: miR-495
is upregulated by E12/E47 in breast cancer stem cells, and promotes
oncogenesis and hypoxia resistance via downregulation of E-cadherin
and REDD1. Oncogene. 30:2463–2474. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ke J, Zhao Z, Hong SH, Bai S, He Z, Malik
F, Xu J, Zhou L, Chen W, Martin-Trevino R, et al: Role of
microRNA221 in regulating normal mammary epithelial hierarchy and
breast cancer stem-like cells. Oncotarget. 6:3709–3721. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Okuda H, Xing F, Pandey PR, Sharma S,
Watabe M, Pai SK, Mo YY, Iiizumi-Gairani M, Hirota S, Liu Y, et al:
miR-7 suppresses brain metastasis of breast cancer stem-like cells
by modulating KLF4. Cancer Res. 73:1434–1444. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jiang F, Li Y, Mu J, Hu C, Zhou M, Wang X,
Si L, Ning S and Li Z: Glabridin inhibits cancer stem cell-like
properties of human breast cancer cells: An epigenetic regulation
of miR-148a/SMAd2 signaling. Mol Carcinog. 55:929–940. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Qian P, Banerjee A, Wu ZS, Zhang X, Wang
H, Pandey V, Zhang WJ, Lv XF, Tan S, Lobie PE and Zhu T: Loss of
SNAIL regulated miR-128-2 on chromosome 3p22.3 targets multiple
stem cell factors to promote transformation of mammary epithelial
cells. Cancer Res. 72:6036–6050. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chen W, Zhou S, Mao L, Zhang H, Sun D,
Zhang J, Li J and Tang JH: Crosstalk between TGF-β signaling and
miRNAs in breast cancer metastasis. Tumour Biol. 37:10011–10019.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yin J, Zheng G, Jia X, Zhang Z, Zhang W,
Song Y, Xiong Y and He Z: A Bmi1-miRNAs cross-talk modulates
chemotherapy response to 5-fluorouracil in breast cancer cells.
PLoS One. 8:e732682013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wu MY, Fu J, Xiao X, Wu J and Wu RC:
MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7
in breast cancer. Cancer Lett. 354:311–319. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Takahashi RU, Miyazaki H, Takeshita F,
Yamamoto Y, Minoura K, Ono M, Kodaira M, Tamura K, Mori M and
Ochiya T: Loss of microRNA-27b contributes to breast cancer stem
cell generation by activating ENPP1. Nat Commun. 6:73182015.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang HJ, Guo YQ, Tan G, Dong L, Cheng L,
Li KJ, Wang ZY and Luo HF: miR-125b regulates side population in
breast cancer and confers a chemoresistant phenotype. J Cell
Biochem. 114:2248–2257. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Vilquin P, Donini CF, Villedieu M, Grisard
E, Corbo L, Bachelot T, Vendrell JA and Cohen PA: MicroRNA-125b
upregulation confers aromatase inhibitor resistance and is a novel
marker of poor prognosis in breast cancer. Breast Cancer Res.
17:132015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhu Y, Yu F, Jiao Y, Feng J, Tang W, Yao
H, Gong C, Chen J, Su F, Zhang Y and Song E: Reduced miR-128 in
breast tumor-initiating cells induces chemotherapeutic resistance
via Bmi-1 and ABCC5. Clin Cancer Res. 17:7105–7115. 2011.
View Article : Google Scholar : PubMed/NCBI
|
